|
Volume 18, Issue 3 (May 2016) 18, 444–445; DOI:10.4103/1008-682X.164920
Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
Jeanny B Aragon-Ching
Clinical Program Director of Genitourinary Cancers, INOVA Dwight and Martha Schar Cancer Institute, 8505 Arlington Boulevard, Suite 100, Fairfax, VA, USA
Correspondence: Dr. JB Aragon-Ching (Jeanny. Aragon-Ching@inova.org)
27-Oct-2015
| Abstract |
|
Abstract
CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who received chemotherapy with ADT have revolutionized the treatment of metastatic castration-sensitive prostate cancer. In addition to overall survival, secondary endpoints such as time to castration resistance, PSA response were also significant for the patients who received early chemotherapy.
Full Text |
PDF |
中文摘要 |
|
| |
| Browse: 3100 |
|
